How to use Rozelixizumab

Rozanolixizumab (Rozanolixizumab) is a new immunotherapy drug used to treat patients with myasthenia gravis (gMG; rare disease ) who are positive for anti-acetylcholine receptor antibodies (AChR) or anti-MuSK antibodies. As the first anti-FcRn monoclonal antibody in the form of subcutaneous injection, it blocks the function of nascent Fc receptors and reduces the level of pathogenic autoantibodies in the body, thereby alleviating neuromuscular conduction disorders. Since the mechanism of action of this drug is delicate and its efficacy varies among individuals, its use must strictly follow the recommended specifications to ensure the safety and effectiveness of the treatment.

Rozelixizumab is only available for subcutaneous injection and is not available for intravenous infusion or intramuscular injection. Before using the drug, the doctor needs to determine the dosage based on the patient's weight. For patients weighing less than 50 kg, the dose per injection is 420 mg; for patients weighing between 50 and 100 kg, 560 mg; and for patients weighing over 100 kg, 840 mg. The corresponding infusion volumes are 3ml, 4ml and 6ml respectively. Each patient needs to inject the drug solution through an infusion pump. The recommended maximum infusion rate is 20 ml per hour to ensure that the drug enters the subcutaneous tissue slowly and stably and reduces injection-related adverse reactions.

The standard course of treatment is subcutaneous injection once a week, lasting for 6 weeks is a complete course of treatment. Before each dose, it is recommended to assess whether the patient's vaccination status needs to be updated. In particular, the use of live vaccines should be completed at least 4 weeks before treatment to avoid immune interference. In addition, after completing a course of treatment, whether to continue the next cycle needs to be comprehensively evaluated by the doctor based on the patient's condition control, changes in antibody levels, and side effects. The safety of repeated dosing within 63 days of the start of the previous course of treatment has not been fully studied, so it is recommended to avoid too frequent treatment.

If the patient misses an injection due to personal reasons, he or she can continue the treatment as long as the dose is filled up within 4 days after the scheduled time; if it exceeds 4 days, the treatment plan needs to be re-evaluated.

Reference materials:https://www.drugs.com/rystiggo.html